Harvard Bioscience plans to divest Capital Equipment business.
In 2004, Harvard Bioscience's Capital Equipment business sales fell 21.0% to $27.8 million to account for 30% of total revenues. Harvard Bioscience's operating profit declined 42.8% (see IBO 3/31/05). In 2004, four products lines (the COPAS flow cytometer, MIAS automated microscope, Genomic Solutions microarray products, Cartesian Nanolitre dispensers) accounted for 70% of the Capital Equipment's revenues, according to a 2005 investor presentation. The business was largely created through the acquisition of distressed product lines. Last year, the Genomic Solutions unit was reorganized following a significant decline in sales and an operating loss (see IBO 7/31/04).
|Printer friendly Cite/link Email Feedback|
|Comment:||Harvard Bioscience plans to divest Capital Equipment business.|
|Publication:||Instrument Business Outlook|
|Article Type:||Brief Article|
|Date:||Jul 31, 2005|
|Previous Article:||Invitrogen to acquire BioSource, beating out Bio-Rad.|
|Next Article:||Whatman CEO designate changes his mind.|